{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:55:01Z","timestamp":1793768101496,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.blre.2024.101242","type":"journal-article","created":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T21:36:54Z","timestamp":1728250614000},"page":"101242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["From MGUS to multiple myeloma: Unraveling the unknown of precursor states"],"prefix":"10.1016","volume":"68","author":[{"given":"Gil","family":"Hevroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounika","family":"Vattigunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.blre.2024.101242_bb0005","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2024.101242_bb0010","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.blre.2024.101242_bb0015","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2024.101242_bb0020","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101242_bb0025","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/hematology.2021000303","article-title":"Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events","volume":"2021","author":"Landgren","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"10.1016\/j.blre.2024.101242_bb0030","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.blre.2024.101242_bb0035","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2024.101242_bb0040","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jamaoncol.2019.4659","article-title":"Moving from cancer burden to cancer genomics for smoldering myeloma: a review","volume":"6","author":"Maura","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.blre.2024.101242_bb0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.seminoncol.2022.01.006","article-title":"Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions","volume":"49","author":"Chojnacka","year":"2022","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2024.101242_bb0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0002-9343(57)90335-2","article-title":"Glycoproteins in serum from patients with myeloma, macroglobulinemia and related conditions","volume":"22","author":"Laurell","year":"1957","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2024.101242_bb0055","first-page":"1","article-title":"Studies on \u201cabnormal\u201d serum globulins (M-components) in myeloma, macroglobulinemia and related diseases","volume":"367","author":"Heremans","year":"1961","journal-title":"Acta Med Scand Suppl"},{"issue":"5","key":"10.1016\/j.blre.2024.101242_bb0060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.0954-6820.1984.tb05032.x","article-title":"Benign monoclonal gammapathy","volume":"216","author":"Waldenstr\u00f6m","year":"1984","journal-title":"Acta Med Scand"},{"issue":"5","key":"10.1016\/j.blre.2024.101242_bb0065","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/ajh.23204","article-title":"Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"87","author":"Rajkumar","year":"2012","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.blre.2024.101242_bb0070","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2024.101242_bb0075","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","article-title":"Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden","volume":"123","author":"Turesson","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2024.101242_bb0080","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"9727","key":"10.1016\/j.blre.2024.101242_bb0085","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.blre.2024.101242_bb0090","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.blre.2024.101242_bb0095","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1182\/blood.2021011670","article-title":"How I approach smoldering multiple myeloma","volume":"140","author":"Vaxman","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2024.101242_bb0100","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2024.101242_bb0105","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2024.101242_bb0110","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","article-title":"The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma","volume":"1","author":"Sigurdardottir","year":"2015","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.blre.2024.101242_bb0115","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s41375-019-0419-7","article-title":"Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma","volume":"33","author":"Goyal","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2024.101242_bb0120","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","article-title":"Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies","volume":"11","author":"R\u00f6gnvaldsson","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.blre.2024.101242_bb0125","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","article-title":"The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells","volume":"17","author":"L\u00f3pez-Corral","year":"2011","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2024.101242_bb0130","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.blre.2024.101242_bb0135","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.blre.2024.101242_bb0140","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11914-018-0479-z","article-title":"Contributions of the bone microenvironment to monoclonal gammopathy of undetermined significance pathogenesis","volume":"16","author":"G\u00e1mez","year":"2018","journal-title":"Curr Osteoporos Rep"},{"issue":"4","key":"10.1016\/j.blre.2024.101242_bb0145","first-page":"313","article-title":"Single-cell profiling in multiple myeloma: insights, problems, and promises","volume":"142","author":"Samur","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2024.101242_bb0150","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T11:58:04Z","timestamp":1731585484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"alternative-id":["S0268960X24000754"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101242","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From MGUS to multiple myeloma: Unraveling the unknown of precursor states","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101242"}}